DDInter1881 DDInter782
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zaleplon
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lipoic acid
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin glargine
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramelteon
Troglitazone {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Zaleplon
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Lipoic acid
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Troglitazone may lead to a major life threatening interaction when taken with Mipomersen